http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 09:10:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Clearpoint+Neuro+Inc.+%28CLPT%29+PT+Raised+to+%2425+at+Stifel/26663793.html Stifel analyst Tom Stephan raised the price target on Clearpoint Neuro Inc. (NASDAQ: CLPT) to $25.00 (from $16.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Clearpoint+Neuro+Inc.+%28CLPT%29+PT+Raised+to+%2425+at+Stifel/26663793.html Thu, 18 Jun 2026 09:10:54 -0400 CLPT http://www.streetinsider.com/Analyst+PT+Change/Clearpoint+Neuro+Inc.+%28CLPT%29+PT+Raised+to+%2430+at+B.Riley/26663360.html B.Riley analyst Kyle Bauser raised the price target on Clearpoint Neuro Inc. (NASDAQ: CLPT) to $30.00 (from $20.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Clearpoint+Neuro+Inc.+%28CLPT%29+PT+Raised+to+%2430+at+B.Riley/26663360.html Thu, 18 Jun 2026 08:33:26 -0400 CLPT http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660461.html si-local-file:///var/storage/secattach/20260617/26660461.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660461.html Wed, 17 Jun 2026 16:33:00 -0400 CLPT O.07426235 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660461.html si-local-file:///var/storage/secattach/20260617/26660461.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660461.html Wed, 17 Jun 2026 16:33:00 -0400 CLPT O.07426235 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660439.html si-local-file:///var/storage/secattach/20260617/26660439.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660439.html Wed, 17 Jun 2026 16:32:00 -0400 CLPT O.07426235 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660439.html si-local-file:///var/storage/secattach/20260617/26660439.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ClearPoint+Neuro%2C+Inc.+++++++++++++++++Filed+by%3A+BURNETT+JOSEPH/26660439.html Wed, 17 Jun 2026 16:32:00 -0400 CLPT O.07426235 http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Press+Releases/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html <p><strong>These companies are Pushing Boundaries, including the Blood Brain Barrier</strong></p><p>DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Jpv3kdfRQoI7Fa-_kzD05hBD482eekdDCquksqbAPzmD6POS6Jre87nM37zg1AL9yCSduitFpRT_gSfQDvEHN8QSQa6Mj90dFenkPaVsS8o=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.</p> <p><strong>NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=11yFTWuW9hHrVr_25YuXTahi01owvT-_xQNw5LBirLcIv0I5KlMk5otgfZrc22iUMRxYJiVEqJrvPvlHmDzjHvpO4Fg9J0ZISIQfAqw1vlA=" rel="nofollow" target="_blank"><strong>NeOnc</strong></a> <strong>(NASDAQ: NTHI)</strong> is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New http://www.streetinsider.com/Globe+Newswire/Biotech%27s+New+Frontier%3A+Companies+Breaking+Through+Medicine%27s+Toughest+Barriers/26658276.html Wed, 17 Jun 2026 10:37:33 -0400 CLPT ICCM NTHI QURE http://www.streetinsider.com/Investing/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html <p>Investing.com -- ClearPoint Neuro (NASDAQ:CLPT) shares rose 27% Wednesday following UniQure's announcement that the FDA agreed its 3-year Phase I/II study data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease.</p><p>UniQure's lead Huntington's disease therapy, AMT-130, is administered using ClearPoint's navigation system and SmartFlow cannula.</p><p>UniQure (NASDAQ:QURE) said the FDA communicated during a recent Type B meeting that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in the third quarter of 2026.</p><p>The FDA is seeking to http://www.streetinsider.com/Investing/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html Wed, 17 Jun 2026 07:21:11 -0400 CLPT QURE http://www.streetinsider.com/Investing/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html <p>Investing.com -- ClearPoint Neuro (NASDAQ:CLPT) shares rose 27% Wednesday following UniQure's announcement that the FDA agreed its 3-year Phase I/II study data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease.</p><p>UniQure's lead Huntington's disease therapy, AMT-130, is administered using ClearPoint's navigation system and SmartFlow cannula.</p><p>UniQure (NASDAQ:QURE) said the FDA communicated during a recent Type B meeting that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in the third quarter of 2026.</p><p>The FDA is seeking to http://www.streetinsider.com/Investing/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html Wed, 17 Jun 2026 07:21:11 -0400 CLPT QURE http://www.streetinsider.com/Momentum+Movers/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html <p>Investing.com -- ClearPoint Neuro (NASDAQ:CLPT) shares rose 27% Wednesday following UniQure's announcement that the FDA agreed its 3-year Phase I/II study data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease.</p><p>UniQure's lead Huntington's disease therapy, AMT-130, is administered using ClearPoint's navigation system and SmartFlow cannula.</p><p>UniQure (NASDAQ:QURE) said the FDA communicated during a recent Type B meeting that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in the third quarter of 2026.</p><p>The FDA is seeking to http://www.streetinsider.com/Momentum+Movers/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html Wed, 17 Jun 2026 07:21:11 -0400 CLPT QURE http://www.streetinsider.com/Momentum+Movers/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html <p>Investing.com -- ClearPoint Neuro (NASDAQ:CLPT) shares rose 27% Wednesday following UniQure's announcement that the FDA agreed its 3-year Phase I/II study data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease.</p><p>UniQure's lead Huntington's disease therapy, AMT-130, is administered using ClearPoint's navigation system and SmartFlow cannula.</p><p>UniQure (NASDAQ:QURE) said the FDA communicated during a recent Type B meeting that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in the third quarter of 2026.</p><p>The FDA is seeking to http://www.streetinsider.com/Momentum+Movers/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html Wed, 17 Jun 2026 07:21:11 -0400 CLPT QURE http://www.streetinsider.com/Trader+Talk/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html <p>Investing.com -- ClearPoint Neuro (NASDAQ:CLPT) shares rose 27% Wednesday following UniQure's announcement that the FDA agreed its 3-year Phase I/II study data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease.</p><p>UniQure's lead Huntington's disease therapy, AMT-130, is administered using ClearPoint's navigation system and SmartFlow cannula.</p><p>UniQure (NASDAQ:QURE) said the FDA communicated during a recent Type B meeting that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in the third quarter of 2026.</p><p>The FDA is seeking to http://www.streetinsider.com/Trader+Talk/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html Wed, 17 Jun 2026 07:21:11 -0400 CLPT QURE http://www.streetinsider.com/Trader+Talk/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html <p>Investing.com -- ClearPoint Neuro (NASDAQ:CLPT) shares rose 27% Wednesday following UniQure's announcement that the FDA agreed its 3-year Phase I/II study data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease.</p><p>UniQure's lead Huntington's disease therapy, AMT-130, is administered using ClearPoint's navigation system and SmartFlow cannula.</p><p>UniQure (NASDAQ:QURE) said the FDA communicated during a recent Type B meeting that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval. The company intends to submit the BLA in the third quarter of 2026.</p><p>The FDA is seeking to http://www.streetinsider.com/Trader+Talk/ClearPoint+Neuro+stock+surges+on+peer%27s+FDA+approval+plan/26656817.html Wed, 17 Jun 2026 07:21:11 -0400 CLPT QURE http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Clearpoint+Neuro+Inc.+%28CLPT%29/26621533.html <p>Stifel analyst Tom Stephan reiterated a Buy rating and $16.00 price target on Clearpoint Neuro Inc. (NASDAQ: CLPT).</p><p>The analyst commented, "We attended the biennial American Society for Stereotactic and Functional Neurosurgery (ASSFN) meeting last week, a specialized conference with strong applicability to CLPT's neurosurgery ecosystem. To that end, key technology-related themes at the meeting included drug delivery, braincomputer interface (BCI) implants, and focused ultrasound—all of which are highly relevant to CLPT.Coming away from the conference, we gained an even greater appreciation for the comprehensiveness of CLPT’s neurosurgery solutions, as the company (especially now with focused ultrasound) uniquely is a true http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Clearpoint+Neuro+Inc.+%28CLPT%29/26621533.html Tue, 09 Jun 2026 09:09:56 -0400 CLPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+04++Filed+by%3A+Richards+Timothy+T./26617790.html si-local-file:///var/storage/secattach/20260608/26617790.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+04++Filed+by%3A+Richards+Timothy+T./26617790.html Mon, 08 Jun 2026 16:30:00 -0400 CLPT O.07426235 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+04++Filed+by%3A+Richards+Timothy+T./26617790.html si-local-file:///var/storage/secattach/20260608/26617790.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+04++Filed+by%3A+Richards+Timothy+T./26617790.html Mon, 08 Jun 2026 16:30:00 -0400 CLPT O.07426235 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Richards+Timothy+T./26592204.html si-local-file:///var/storage/secattach/20260602/26592204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Richards+Timothy+T./26592204.html Tue, 02 Jun 2026 16:30:00 -0400 CLPT O.07426235 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Richards+Timothy+T./26592204.html si-local-file:///var/storage/secattach/20260602/26592204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ClearPoint+Neuro%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Richards+Timothy+T./26592204.html Tue, 02 Jun 2026 16:30:00 -0400 CLPT O.07426235